American journal of translational research · 2025
Efficacy and safety of ixazomib-lenalidomide-dexamethasone in relapsed/refractory multiple myeloma patients.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Huang Xufei, Zhu Yirong, Wen Xuemei, Li Xiaofan
Аннотация
OBJECTIVE: To evaluate the therapeutic efficacy and safety profile of the ixazomib-lenalidomide-dexamethasone (IRd) combination in patients with relapsed/refractory multiple myeloma (RRMM).
METHODS: Between May 2022 and January 2025, 120 RRMM patients were assigned to a control group (n=52) receiving lenalidomide-dexamethasone (Rd) or an observation group (n=68) treated with IRd. Comparative analyses were conducted to assess therapeutic effectiveness, safety (fatigue, infections, gastrointestinal disturbances, peripheral neuropathy, thrombocytopenia, and leukopenia), bone turnover markers (alkaline phosphatase [ALP], osteocalcin [BGP], C-terminal telopeptide of type I collagen [CTX-I]), inflammatory markers (C-reactive protein [CRP], interleukin-6 [IL-6], tumor necrosis factor-alpha [TNF-α]), and other serum biomarkers (erythrocyte sedimentation rate [ESR], M protein, β2-microglobulin [β2-MG]). Predictive factors for treatment response were identified through univariate and multivariate regression modeling.
RESULTS: The observation group demonstrated superior overall effectiveness compared to the control group (P<0.05), without significant differences in adverse event incidence (P>0.05). Post-treatment evaluations showed significantly greater reductions in CTX-I, CRP, IL-6, TNF-α, ESR, M-protein, and β2-MG levels in the IRd cohort, alongside increased ALP and BGP levels (all P<0.05). Univariate analysis identified Revised International Staging System (R-ISS) classification, IL-6, ESR, M-protein levels, and treatment protocol as significant predictors of therapeutic response (all P<0.05). Multivariate modeling confirmed M-protein concentration as an independent prognostic factor (P<0.05).
CONCLUSIONS: The IRd regimen demonstrates enhanced clinical efficacy in RRMM management, maintaining a safety profile comparable to the conventional Rd regimen. Furthermore, it effectively improves bone metabolism, reduces serum inflammation, and modulates serum biochemical parameters. Elevated M-protein expression correlates with poorer treatment outcome in RRMM.
METHODS: Between May 2022 and January 2025, 120 RRMM patients were assigned to a control group (n=52) receiving lenalidomide-dexamethasone (Rd) or an observation group (n=68) treated with IRd. Comparative analyses were conducted to assess therapeutic effectiveness, safety (fatigue, infections, gastrointestinal disturbances, peripheral neuropathy, thrombocytopenia, and leukopenia), bone turnover markers (alkaline phosphatase [ALP], osteocalcin [BGP], C-terminal telopeptide of type I collagen [CTX-I]), inflammatory markers (C-reactive protein [CRP], interleukin-6 [IL-6], tumor necrosis factor-alpha [TNF-α]), and other serum biomarkers (erythrocyte sedimentation rate [ESR], M protein, β2-microglobulin [β2-MG]). Predictive factors for treatment response were identified through univariate and multivariate regression modeling.
RESULTS: The observation group demonstrated superior overall effectiveness compared to the control group (P<0.05), without significant differences in adverse event incidence (P>0.05). Post-treatment evaluations showed significantly greater reductions in CTX-I, CRP, IL-6, TNF-α, ESR, M-protein, and β2-MG levels in the IRd cohort, alongside increased ALP and BGP levels (all P<0.05). Univariate analysis identified Revised International Staging System (R-ISS) classification, IL-6, ESR, M-protein levels, and treatment protocol as significant predictors of therapeutic response (all P<0.05). Multivariate modeling confirmed M-protein concentration as an independent prognostic factor (P<0.05).
CONCLUSIONS: The IRd regimen demonstrates enhanced clinical efficacy in RRMM management, maintaining a safety profile comparable to the conventional Rd regimen. Furthermore, it effectively improves bone metabolism, reduces serum inflammation, and modulates serum biochemical parameters. Elevated M-protein expression correlates with poorer treatment outcome in RRMM.